Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

This study is helping Latino/Hispanic transgender women (TGW) and gay or bisexual men (GBM) in the Southern United States start and stay on long-acting injectable HIV prevention medication (called PrEP). The study uses a long-acting injectable form of PrEP called lenacapavir, given twice a year instead of daily pills. **You may be eligible if...** - You were assigned male sex at birth - You identify as Hispanic/Latine - You are 18 or older and HIV-negative - You have had sexual activity with someone assigned male at birth, or identify as a gay/bisexual man or transgender woman - You weigh at least 77 lbs (35 kg) - You are interested in HIV prevention (PrEP) **You may NOT be eligible if...** - You are living with HIV - You were assigned female sex at birth - You are already taking oral PrEP and are unwilling to switch to injectable lenacapavir - You have severe kidney or liver disease - You take medications that significantly interact with lenacapavir Talk to your doctor to see if this trial is right for you.